Despite multiple new therapies that have transformed the management of type 2 diabetes in recent years, for type 1 diabetes, the primary treatment remains insulin alone. This highlights a substantial unmet need for additional treatments that can be used alongside insulin to improve outcomes for those living with type 1 diabetes.
During the symposium, Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes—Phase 1 and 2 Results, a panel of experts will discuss clinical trial results for CT-868 in type 1 diabetes. The session will be held on Friday, June 5 from 5:30–6:30 p.m. in Great Hall A of the Ernest N. Morial Convention Center. On-demand access to recorded presentations will be available to registered participants following the conclusion of the 2026 Scientific Sessions, from June 10–August 10.
Klara Klein, MD, PhD, Assistant Professor of Endocrinology and Metabolism and Director of the Endocrine Diabetes and Obesity Clinical Research Unit at the University of North Carolina at Chapel Hill, will discuss the phase 2 trial design, study population, and key glycemic endpoints.
“Incretin therapies have demonstrated really important disease-modifying effects in type 2 diabetes, but whether those beneficial effects extend to people with type 1 diabetes isn’t established,” Dr. Klein said.
Although these medications are currently used off-label, many people with type 1 diabetes lack access to them because health insurance does not cover them for type 1 diabetes. Additional research is also needed to establish the safety and efficacy of incretin therapies in type 1 diabetes, which could pave the way for on-label approval of these medications.
The phase 2 trial is evaluating the safety and efficacy of CT-868, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for type 1 diabetes. The primary outcome was improvement in A1C. Secondary outcomes included continuous glucose monitoring metrics, weight, and the effects on insulin dose and body composition.
Richard Pratley, MD, Senior Investigator at Advent Health, will discuss a proof-of-mechanism study of CT-868 in type 1 diabetes. Jeremy Pettus, MD, Professor of Medicine at the University of California, San Diego, will cover other important outcomes in the phase 2 study, such as weight.
The results of the phase 2 trial are pending but will be presented during this symposium.
“While the study results are not yet public, the program is moving forward into phase 3 development, including in populations who may benefit from disease-modifying effects, like kidney protection,” Dr. Klein said. “We are very excited to give more details in the symposium.”
Register Today for the 2026 Scientific Sessions
Register to join us in New Orleans June 5–8 to learn about the latest advances in diabetes research, prevention, and care. After the meeting, registered participants will have on-demand access to recorded presentations.
